My mammaprint (gene profile) results: Low Risk. 10 year Distant Metastasis-Free Survival prior to treatment ~90%. What this basically says is that I can expect my risk to be reduced up to 50% with adjuvant hormonal therapy.
My targetprint (gene expression) analysis: ER (estrogen) Positive, PR (progesterone) Positive, HER2 Negative. ER/PR expression predicts potential hormonal therapy benefit. The targetprint quantitative gene results enable clarification of uncertain or borderline immunohistochemistry results.
My blueprint (molecular subtyping) results: My cancer is what they call "Luminal-type" and are typically hormone receptor positive tumors predictive for hormonal therapy sensitivity. Mammaprint "Low Risk" and "Luminal-type" combination cancer is predicted to have a clinical course similar to Luminal A, usually treated with hormonal therapy.